Monday, November 20, 2023
Chiesi Farmaceutici S.p.A, also known as Chiesi Group, a global biopharmaceuticals and healthcare organization with a focus on research, has entered into a Licensing Agreement with Haisco Pharmaceutical Group Co. Ltd (Haisco Pharmaceutical). The agreement covers the collaborative development, manufacturing, and commercialization of HSK31858, a novel reversible dipeptidyl peptidase 1 (DPP1) inhibitor designed for respiratory diseases. This collaboration extends to regions outside China and adjacent territories, including Hong Kong SAR, Macau SAR, and Taiwan District.
Currently in Phase 2 trials in China, HSK31858 is an oral, potent, and highly selective small molecule DPP1 inhibitor with potential as an anti-inflammatory agent in bronchiectasis.
Chiesi's strategic objective is to expand its product portfolio in the respiratory field, reinforcing its commitment to addressing severe respiratory diseases with significant unmet medical needs.
Thomas Eichholtz, Head of Global Research and Development at Chiesi Group, expressed the company's dedication to developing innovative medicines that enhance the lives of patients facing limited treatment options. He emphasized the significance of HSK31858 as a valuable addition to Chiesi's pipeline and highlighted the opportunity for synergy between the partners' extensive experience in respiratory research.
Xiulian Fan, General Manager at Haisco Pharmaceutical, sees this collaboration as a pivotal step in their global expansion strategy. He expressed satisfaction that HSK31858 will eventually benefit patients worldwide. Fan acknowledged Chiesi's substantial commitment and expertise in respiratory drug development, anticipating that the partnership would maximize the value of HSK31858.
The agreement outlines an upfront payment from Chiesi to Haisco, along with contingent milestone payments, including royalties based on product sales.